Trials / Completed
CompletedNCT02546817
Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS
Eliquis (Apixaban) Regulatory Postmarketing Surveillance In Real World Practice (rPMS) For Venous Thromboembolism (VTE) Treatment And Prevention Of Recurrent VTE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 29 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To assess the real-world safety/effectiveness of Eliquis in Korean venous thromboembolism (VTE) patients and patient characteristics that are associated with bleeding among patients taking Eliquis. To identify factors that might be associated with the safety and effectiveness profile in Korean VTE patients.
Conditions
Timeline
- Start date
- 2015-11-30
- Primary completion
- 2017-09-29
- Completion
- 2017-09-29
- First posted
- 2015-09-11
- Last updated
- 2017-10-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02546817. Inclusion in this directory is not an endorsement.